Forte Biosciences, Inc. (FBRX) Stock Score, Valuation & Financial Research

Forte Biosciences, Inc. is in the Healthcare sector and Biotechnology industry. It is reviewed using Wall Street Score's company-strength, valuation, growth and financial-health framework. A complete Wall Street Score is not currently available.

Quick answer for FBRX

Forte Biosciences, Inc. does not currently have a complete Wall Street Score. The stored market price is USD 76.99. These figures are a research snapshot, not a buy or sell recommendation.

What Forte Biosciences, Inc. does

Forte Biosciences, Inc. is a U.S.-based biopharmaceutical company currently in its clinical development phase. The firm's key initiative involves advancing the FB-102 program, which is designed to tackle a variety of autoimmune conditions, notably vitiligo and alopecia areata. Their main offices are situated in Dallas, Texas.

Company business and revenue

Research reporting period: 2025-12-31. A research update is not a new financial filing.

How the company makes money

Forte Biosciences is a clinical-stage biopharmaceutical company that does not currently generate revenue from product sales. Its business model relies on raising capital through equity offerings to fund the research and development of its proprietary therapeutic candidates, specifically FB102, for autoimmune and autoimmune-related diseases.

Products and services

  • The company is currently focused on the development of FB102, a proprietary anti-CD122 antibody candidate being evaluated for potential applications in autoimmune diseases such as celiac disease and vitiligo.

Brands and product families

  • FB102 — Lead clinical-stage proprietary anti-CD122 antibody candidate. Source

Customer types

Clinical trial patients.

Suppliers, materials and equipment

  • Contract Manufacturing Organizations — The company relies on third-party contract manufacturing organizations for the production of its clinical trial materials. Source

Business strengths to evaluate

  • Proprietary FB102 molecule with potential broad autoimmune applications Source

Business risks and research considerations

  • History of operating losses and expectation of future losses Source
  • Dependence on the success of a single product candidate, FB102 Source
  • Need for additional capital to fund operations and clinical trials Source

Sources: Company research source · FB102

Company research refreshed 2026-10-12. This is saved research, not a live check of company relationships. Check the reporting period and source disclosures. Financial figures and scores follow their separate update schedules.

FBRX financial snapshot

Statement amounts: USD. Quote amounts: USD. No exchange-rate conversion is performed in this snapshot. Market-capitalization currency is not supplied by this projection.

Wall Street Score:
Not currently available
Stored price:
USD 76.99
Market capitalization:
1.58B (currency not supplied)
Revenue:
USD 0.00
Net income:
USD -87.94M
Free cash flow:
USD -51M
Cash:
USD 49.63M
Total debt:
USD 0.00
EPS:
USD -4.59

What stands out

  • Free cash flow is USD -51M, negative for the stored period.
  • The balance sheet shows USD 49.63M of cash versus USD 0.00 of total debt, an excess of cash over debt on these two reported measures.
  • The current research record carries a fundamental change risk warning, which should be reviewed alongside the score.

Company-specific financial comparisons

The following are calculated from saved company data, not forecasts or statements about future performance. Differences in reporting dates or units can make a ratio misleading; verify the original filings.

  • Cash exceeds debt by USD 49.63M using the stored balance-sheet values. This does not include other obligations or restricted cash.

Questions worth answering for FBRX

Use these questions to check the stored figures against the latest company filings. They identify issues to investigate; they are not findings about management's plans or future results.

  • How long can FBRX fund negative free cash flow using its current cash position before it may need more debt or new shares?
  • How is FBRX likely to use its cash advantage: reinvestment, acquisitions, debt reduction, dividends or buybacks?
  • What specifically needs to improve for FBRX to reach sustainable profitability?
  • What does the current fundamental change risk warning mean for the reliability or interpretation of FBRX's score?

What the numbers mean

A complete valuation score is not currently available, so valuation should be checked using the available earnings, cash-flow and price data.

A complete financial score is not currently available, so investors should review cash, debt, earnings and cash flow directly.

A strong company and an attractive stock price are not always the same thing. Revenue, earnings, free cash flow, debt, management quality, competitive advantage and valuation should be considered together. Wall Street Score organizes these inputs into a consistent research framework so investors can identify what deserves deeper review.

Data freshness: Financial data last refreshed 2026-10-01.

Research-input completeness: 64% of the scoring inputs required for this public page are currently available.

How to research FBRX

Start by understanding how the company makes money. Then compare revenue and earnings trends, cash generation, debt, liquidity and valuation. Review the company's latest filings and earnings reports before acting on any score or model estimate.

Learn how to analyze a stock · Read the Wall Street Score methodology · Browse other stocks

Data may change as company filings and market prices update. Educational research only; not a buy or sell recommendation.